INTELLIA THERAPEU DL-,01 WKN: A2AG6H ISIN: US45826J1051 Kürzel: NTLA Forum: Aktien Thema: Hauptdiskussion
16,03 USD
+3,89 %+0,60
6. Nov, 23:24:11 Uhr,
UTP Consolidated
Kommentare 427
Summer.76,
23.02.2022 15:32 Uhr
0
Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies
https://www.globenewswire.com/news-release/2022/02/23/2390327/0/en/Intellia-Therapeutics-Enters-Lease-Agreement-to-Build-Manufacturing-Facility-for-its-CRISPR-based-Therapies.html
• State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapies
• New facility in Waltham, Massachusetts expected to be operational in 2024
Summer.76,
15.02.2022 15:07 Uhr
0
Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer
https://finance.yahoo.com/news/intellia-onk-therapeutics-announce-collaboration-123000355.html
Summer.76,
03.02.2022 15:37 Uhr
0
Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics
https://www.globenewswire.com/news-release/2022/02/03/2378394/0/en/Intellia-Therapeutics-Announces-Acquisition-of-Rewrite-Therapeutics.html
d
donnralfo,
12.01.2022 22:18 Uhr
0
So langsam wird's wieder interessant. Ein Boden erkennt man nicht...
Summer.76,
31.12.2021 20:46 Uhr
0
https://www.nasdaq.com/articles/intellias-ntla-crispr-therapies-show-promise-amid-competition
Intellia's (NTLA) CRISPR Therapies Show Promise Amid Competition
Summer.76,
30.12.2021 19:46 Uhr
0
Ja, das Problem mit der Bewertung findet sich nicht nur hier und deshalb hatte ich nach der Durchbruchsmeldung auch meinen Bestand teils reduziert. Investiert bin ich weiterhin, aber von gerechtfertigt lässt sich natürlich nicht unbedingt sprechen 🙃. Eher davon, dass die Zukunft gehandelt wird.
J
JOEVBLACK,
30.12.2021 17:58 Uhr
0
Summer76, Du scheinst der Firma im Derail zu folgen. Ich überlege einnen Einstieg, finde aber die Bewertung ziemlich astronomisch. Ist sie gerexhtfertigt im Vergleich zu anderen Crispr-cas9 companies ?
Summer.76,
22.11.2021 14:54 Uhr
0
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
https://www.globenewswire.com/news-release/2021/11/22/2338871/0/en/Intellia-Therapeutics-Announces-Expansion-of-Ongoing-Phase-1-Study-of-NTLA-2001-to-Include-Adults-with-Transthyretin-Amyloidosis-with-Cardiomyopathy-ATTR-CM.html
Approved protocol amendment enables enrollment of ATTR-CM patients in the ongoing first-in-human study of NTLA-2001, a systemically delivered CRISPR/Cas9-based therapy
B
BobbyBobberson,
04.11.2021 13:02 Uhr
0
Intellia accelerates plans to evaluate ATTR amyloidosis candidate in cardiomyopathy
Nov. 04, 2021 7:59 AM ETIntellia Therapeutics, Inc. (NTLA)By: Jonathan M Block, SA News Editor

Meletios Verras/iStock via Getty Images
Intellia Therapeutics (NASDAQ:NTLA) has decided to accelerate plans to evaluate NTLA-2001, its candidate for ATTR amyloidosis, in patients with cardiomyopathy.
The company said that based on an interim dataset, it is seeking regulatory feedback on inclusion of cardiomyopathy patients in its current phase 1 study.
Intellia is eyeing presenting interim data from part 1, a single-ascending dose portion, and to begin part 2, a single-cohort expansion, in Q1 2022.
Elsewhere in the pipeline, the company is planning to begin enrollment in a phase 1 study of NTLA-2002 for hereditary angioedema by the end of the year.
Also, by 1H 2022, Intellia's plans to nominate its first allogeneic development candidate.
In Q3 2021, Intellia's net loss widened ~158% to $71.6M (0.97 per share basic and diluted) due to a significant decline in collaboration revenue and an increase in R&D expenses
B
BobbyBobberson,
04.11.2021 12:49 Uhr
0
Ist natürlich noch nicht wirklich relevant
B
BobbyBobberson,
04.11.2021 12:49 Uhr
0
Intellia Therapeutics EPS misses by $0.11, misses on revenue
Nov. 04, 2021 7:32 AM ETIntellia Therapeutics, Inc. (NTLA)By: Gaurav Batavia, SA News Editor
Intellia Therapeutics (NASDAQ:NTLA): Q3 GAAP EPS of -$0.97 misses by $0.11.
Revenue of $7.21M (-67.5% Y/Y) misses by $1.45M.
Press Release
Cash, cash equivalents and marketable securities were $1,148.7 million as of September 30, 2021, compared to $597.4 million as of December 31, 2020. The increase was driven by net proceeds of $648.3 million from a follow-on offering in Q3 2021, $45.3 million of net proceeds from the Company’s “At the Market” agreement, $40.8 million in proceeds from employee-based stock plans, and $4.2 million of funding for a cost-sharing agreement received from Regeneron. These increases were offset in part by cash used to fund operations of approximately $187.3 million.
Summer.76,
21.10.2021 13:58 Uhr
1
Etwas ausführlicher:
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
https://www.globenewswire.com/news-release/2021/10/21/2318228/0/en/Intellia-Therapeutics-Receives-U-S-FDA-Orphan-Drug-Designation-for-NTLA-2001-an-Investigational-CRISPR-Therapy-for-the-Treatment-of-Transthyretin-ATTR-Amyloidosis.html
Summer.76,
20.10.2021 18:28 Uhr
0
Intellia granted Orphan Drug designation for transthyretin amyloidosis program
https://newsfilter.io/a/a34daaacd54413360e2cadfaf0fcfc76
• The FDA has granted Orphan Drug designation to Intellia Therapeutics' (NTLA +0.3%) NTLA-2001 treatment for transthyretin amyloidosis ("ATTR").
• The gene editing therapy use a knockout edit to reduce circulating TTR protein levels.
• Intellia is partnered with Regeneron Pharmaceuticals (REGN +0.9%) on NTLA-2001.
• NTLA-2001 was granted Orphan Drug designation by the European Commission in March.
Summer.76,
20.10.2021 15:21 Uhr
0
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress
https://www.globenewswire.com/news-release/2021/10/20/2317270/0/en/Intellia-Therapeutics-Presents-Preclinical-Data-Demonstrating-Advancements-in-its-Broad-Genome-Editing-Capabilities-at-the-2021-European-Society-of-Gene-Cell-Therapy-Annual-Congres.html
• First preclinical data demonstrating Intellia’s allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatments
• Demonstrated lipid nanoparticle-based delivery as a more efficient multiplex gene editing approach for engineered cell therapies as compared to electroporation
• Achieved durable production of normal human alpha-1 antitrypsin protein levels and reduction of endogenous disease-associated protein in non-human primates for the treatment of liver and/or lung manifestations of alpha-1 antitrypsin deficiency (AATD)
• Platform advances support acceleration of future drug development candidates from both Intellia’s in vivo and ex vivo research portfolio
...
Strive,
19.10.2021 15:09 Uhr
0
Kommt dieses Jahr eigentlich noch was an Ergebnissen?🤔
Summer.76,
13.10.2021 14:23 Uhr
1
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
https://www.globenewswire.com/news-release/2021/10/13/2313317/0/en/Intellia-Therapeutics-and-SparingVision-Announce-Strategic-Collaboration-to-Develop-Novel-Ocular-Therapies-Using-CRISPR-Cas9-Technology.html
• Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise
• Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three targets
• Intellia will receive an equity stake in SparingVision and will have an option to obtain exclusive US commercialization rights for ocular therapies for two targets
...
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | SOLAREDGE TECH Hauptdiskussion | -36,62 % | |
2 | DAX Hauptdiskussion | -0,92 % | |
3 | Phunware ab 27.02.24 RS | +9,11 % | |
4 | PLUG POWER Hauptdiskussion | -21,83 % | |
5 | Phunware Hauptdiskussion | +9,11 % | |
6 | AMC ENTERTAINMENT Hauptdiskussion | -1,82 % | |
7 | Plug Power ohne Spam | -21,83 % | |
8 | VW Hauptdiskussion | -4,73 % | |
9 | Nio für normale Kommunikation | -4,93 % | |
10 | ALBEMARLE Hauptdiskussion | -4,55 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | SOLAREDGE TECH Hauptdiskussion | -36,62 % | |
2 | Phunware ab 27.02.24 RS | +9,11 % | |
3 | PLUG POWER Hauptdiskussion | -21,83 % | |
4 | Phunware Hauptdiskussion | +9,11 % | |
5 | AMC ENTERTAINMENT Hauptdiskussion | -1,82 % | |
6 | Plug Power ohne Spam | -21,83 % | |
7 | VW Hauptdiskussion | -4,73 % | |
8 | ALBEMARLE Hauptdiskussion | -4,55 % | |
9 | Nio für normale Kommunikation | -4,93 % | |
10 | NIO INC.A S.ADR DL-,00025 Hauptdiskussion | -4,93 % | Alle Diskussionen |